ICT-107 / Targepeutics, EOM Pharma - LARVOL DELTA

A 5-Year Update on the Clinical Development of Cancer Cell-Based Vaccines for Glioblastoma Multiforme. (PubMed, Pharmaceuticals (Basel)) - "This review provides an extensive update on recent clinical trials involving various cancer cell vaccines, including ICT-107, the α-type-1 DC vaccine, and others...We discuss the details of these trials along with the potential mechanism of vaccine efficacy and immune activations. The findings of these trials highlight the significance of a personalized immunotherapy approach and suggest that patient stratification could significantly advance the clinical management of GBM."

Journal • Review • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma (clinicaltrials.gov) - P3 | N=234 | Suspended | Sponsor: Precision Life Sciences Group | N=414 ➔ 234 | Trial completion date: Dec 2021 ➔ Dec 2025 | Trial primary completion date: Dec 2019 ➔ Dec 2025

Enrollment change • Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

AN ANTICANCER DRUG COCKTAIL OF Three Kinase Inhibitors Improved Response to a DENDRITIC CELL-BASED CANCER VACCINE. (PubMed, Cancer Immunol Res) - "We identified AKT inhibitor MK2206, DNA-PK inhibitor NU7441, and MEK inhibitor trametinib as the compounds most effective at modulating moDC immunogenicity...MKNUTRA treatment imparted to ICT107, a glioblastoma (GBM) DC-based vaccine that has completed phase II trials, an increased ability to stimulate patient-derived autologous CD8 T cells against the brain tumor antigens IL13Rα2 and TRP2In vivo, treating ICT107 with MKNUTRA, prior to injection into mice with an established GBM tumor, reduced tumor growth kinetics. This response was associated with an increased frequency of tumor-reactive lymphocytes within tumors and in peripheral tissues. These studies broaden the application of targeted anticancer drugs and highlight their ability to increase moDC immunogenicity."

Journal • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

A Randomized Double-Blind Placebo-Controlled Phase 2 Trial Of Dendritic Cell Vaccine ICT-107 In Newly Diagnosed Patients With Glioblastoma. (PubMed, Clin Cancer Res) - "PFSl was significantly improved in ICT-107 treated patients with maintenance of QoL. Patients in the HLA-A2 subgroup showed increased ICT-107 activity clinically and immunologically."

Clinical • Journal • P2 data • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

ImmunoCellular Therapeutics announces asset purchase agreement with private biotechnology company (PRNewswire) - "ImmunoCellular Therapeutics...announced an agreement with a privately held biotechnology company (the "Purchaser") for the purchase of substantially all of ImmunoCellular's remaining clinical and pre-clinical assets, including its preclinical and clinical programs, technology, intellectual property and know-how. ImmunoCellular's therapeutic assets are comprised of ICT-107 (phase 3-ready for glioblastoma), ICT-121 (phase 1 completed for recurrent glioblastoma) and ICT-140 (phase 1/2-ready for ovarian cancer), each of which is a patient-specific dendritic cell-based immunotherapy targeting solid tumors."

Licensing / partnership